Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...

In COVID-19, activation of the lectin pathway is a very early event, occurring prior to hyperinflammation and the innate antibody response.

Three pathways have now been described in the complement system — the classic, alternative and lectin. A fourth, lytic pathway is added by some authors for membrane attack complex.

Its pathogenesis is complex and not well understood, but there is increasing evidence that the lectin-driven complement activation may be behind it. Mannose-binding lectin serine protease 2 (MASP-2) ...

In addition to its lectin pathway inhibitors, the company is advancing its development of antibodies and small-molecule inhibitors against MASP-3 to block activation of the alternative pathway.

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and ...

Omeros Corporation today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 protects against renal injury caused by proteinuria ...